Cheplapharm Arzneimittel

Last updated
Cheplapharm
Company type Gesellschaft mit beschränkter Haftung (GmbH)
IndustryPharmaceutical
FoundedJuly 1998 [1]
Headquarters Mesekenhagen, Germany
Area served
Worldwide
Key people
  • Sebastian F. Braun (CEO)
  • Bianca Y. Juha (CSO)
  • Edeltraud Lafer (COO)
  • Jens Rothstein (CFO) [2]
Productsprescription medications
over-the-counter drugs and other medical products
Revenue Euro 223 million [3]  (2017)
Number of employees
500 [1]  (July 2021)
Parent Braun Beteiligungs GmbH [4]
Website www.cheplapharm.com
Cheplapharm building in a business park in Greifswald 2159 Bild Nr.116, 13x20.jpg
Cheplapharm building in a business park in Greifswald

Cheplapharm Arzneimittel GmbH, headquartered in Greifswald, is a German pharmaceutical company that markets branded drugs, medical products, supplements and cosmetics.

Contents

Cheplapharm is among the most notable small and medium-sized enterprises (SME) in the federal state of Mecklenburg-Western Pomerania, [5] [6] and part of Braun Beteiligungs GmbH, [4] a family owned business conglomerate that is among that state's 25 biggest employers. [7] [8] Subsidiaries of the company are located in Hamburg, Levallois-Perret (France) and Englewood, New Jersey.

Cheplapharm acts as a divestment partner for various large pharmaceutical companies. [9] [10] [11] [12] Since its foundation in 1998, Cheplapharm has acquired exclusive rights for more than 80 drugs and other pharmaceutical products that their developers intended to divest for economic or strategic reasons, generating yearly double-digit growth rates with this international “buy and build“ strategy. As of 2018, the company holds more than 400 pharmaceutical product registrations in over 120 countries worldwide. [3]

History

The company was founded 1998 in Freiburg by Kurt Teubner, who had been working as a manager for Ciba Geigy (now Novartis). The name Cheplapharm derives from the plant based diuretic Cheplaren, [13] one of the first products Teubner acquired. [14]

In 2003, Cheplapharm was bought by the Braun family. The new proprietors moved operations to Mesekenhagen, where Norbert and Dagmar Braun owned another pharmaceutical company, Riemser AG, a spin-off of the Friedrich Loeffler Institute. [15] Their son Sebastian F. Braun assumed the CEO position at Cheplapharm. [14]

Over the years, Cheplapharm has acquired the rights to more than 80 [16] branded pharmaceuticals and medical products from multinational and German pharmaceutical companies. Among them are large corporations like Merck, F. Hoffmann-La Roche, AstraZeneca, Sanofi, Boehringer Ingelheim and Johnson & Johnson as well as midsize businesses like Grünenthal, Klosterfrau or Riemser. [9] Key acquisitions were those of Heminevrin/Distraneurin (a sedative used to treat acute alcohol withdrawal), from AstraZeneca, in 2010, [11] Rohypnol (a hypnotic) and Vesanoid (a leukemia medication, both from F. Hoffmann-La Roche, in 2012), Deursil/Ursolvan (an anti-gallstone medication, from Sanofi in 2014), Dilatrend (a beta blocker), Xenical (an anti-obesity medication) and Anexate (a benzodiazepine antagonist, all three from F. Hoffmann-La Roche [12] in 2016), [17] [18] [19] Konakion and Cymevene (a vitamin K supplement and a virostatic, from F. Hoffmann-La Roche in 2018), [20] Visudyne (a photosensitizer used for photodynamic therapy of the wet form of macular degeneration, from Novartis in 2018) and Sotacor/Sotalex (an antiarrhythmic, from Bristol-Myers Squibb in 2018). [21] [1]

In 2017, Cheplapharm signed a distributorship agreement with an Orexigen Therapeutics subsidiary to market Mysimba, a combination drug for weight loss, in Germany, France and Austria. [22] Cheplapharm also markets several over-the-counter remedies of local renown or niche appeal in Germany. Among them are Reisegold (an antiemetic with Dimenhydrinate, marketed specifically for motion sickness), the valerian extract-based sedative Baldrian Dispert, and a number of herbal tinctures from the 'Thüringer' brand formerly owned by Klosterfrau. [1]

Cheplapharm has expanded its operations by taking over the pharma companies Walter Ritter GmbH & Co., Hamburg (2008), Sanavita Pharmaceuticals, Werne (2012) and Glenwood LCC, New Jersey [23] (2014). The latter company's main product is Potaba, an urological drug. [1] The French subsidiary Cheplapharm France SAS, located in Levallois-Perret, was established in 2016. [24]

In 2017, Cheplapharm founded a joint venture with the German medical technology company Clearum. The venture, by the name of Med-Tec Holding GmbH, is meant to focus on manufacture of medical technology products, research and development. [25] [26] [27] [28] Construction of a new production facility near Rostock has been announced to start in July 2018. [29]

In 2020, the company invested in product portfolios from Takeda and Leo Pharma. [30] The Takeda portfolio, which comprises 17 products, was the company's largest acquisition to date in terms of scope and purchase price (EUR 450 million). [31] [32] In 2021, all rights to the epilepsy drug Rivotril were acquired from Roche, and Astellas took over the approvals for four branded antibiotics and De Nol, [33] a drug against Helicobacter pylori infections, for Russia, Ukraine and other CIS countries. [34]

Products

Cheplapharm owns global or local marketing and distribution rights for a number of prescription drugs that are used in cardiology (Dilatrend, Aldactone, Inhibace, Sotalex/Sotacor, Pertenso, Dopegyt, Natrilix, Vascal), haematooncology (Vesanoid), urology (Potaba), gastroenterology and bariatrics (Deursil/Ursolvan, Cotazym, Xenical, Mysimba), emergency medicine (Anexate), addiction medicine (Heminevrin/Distraneurin), sleep medicine (Rohypnol, Aponal), infection control (Cymevene, Lariam) and ophthalmology (Visudyne).

The company also markets over-the-counter drugs for common health issues (e.g. antiemetics, antacids, antidiarrhoeals, cardiovascular remedies, painkillers, sedatives) and medical products, among them dietary supplements, hot-cold-packs, cold sprays and dermatological care products. [16]

Related Research Articles

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Grünenthal</span> German pharmaceutical company

Grünenthal is a pharmaceutical company headquartered in Aachen in Germany. It was founded in 1946 as Chemie Grünenthal and has been continuously family-owned. The company was the first to introduce penicillin into the German market in the postwar period, after the Allied Control Council lifted its ban.

Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.

<span class="mw-page-title-main">Merz Pharma</span>

Merz Pharma GmbH & Co. KGaA is an internationally active family-owned company, headquartered in Frankfurt am Main, Germany. Merz is the parent company of independent businesses in the fields of aesthetic medicine, therapeutic medicine, and wellness and beauty products with its brands Tetesept and Merz Spezial.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Piritramide</span> Synthetic opioid

Piritramide(R-3365, trade names Dipidolor, Piridolan, Pirium and others) is a synthetic opioid analgesic that is marketed in certain European countries including: Austria, Belgium, Czech Republic, Slovenia, Germany and the Netherlands. It comes in free form, is about 0.75x times as potent as morphine and is given parenterally for the treatment of severe pain. Nausea, vomiting, respiratory depression and constipation are believed to be less frequent with piritramide than with morphine, and it produces more rapid-onset analgesia when compared to morphine and pethidine. After intravenous administration the onset of analgesia is as little as 1–2 minutes, which may be related to its great lipophilicity. The analgesic and sedative effects of piritramide are believed to be potentiated with phenothiazines and its emetic (nausea/vomiting-inducing) effects are suppressed. The volume of distribution is 0.7-1 L/kg after a single dose, 4.7-6 L/kg after steady-state concentrations are achieved and up to 11.1 L/kg after prolonged dosing.

PHOENIX Pharmahandel GmbH & Co KG, headquartered in Mannheim, Baden-Württemberg, is the largest pharmaceutical wholesaler in Germany, and the second largest in Europe, with about 153 distribution centers across the country delivering drugs to approximately 12,000 independent pharmacies. Its PHOENIX Documentation is an internet-based archive offering detailed information on drugs, their components, indications, and effects. The formation of holding company PHOENIX International Beteiligungs GmbH took place. The Phoenix Group is a majority owner of the pharmaceutical wholesalers Purus A.S. in the Czech Republic and Tamro in Finland. The Phoenix Group itself is mostly owned by the pharmaceutical conglomerate Merckle Group.

<span class="mw-page-title-main">Basilea Pharmaceutica</span> Swiss pharmaceutical company

Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled.

<span class="mw-page-title-main">Stada Arzneimittel</span> German pharmaceutical company

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion.

My Medical Education is a search engine for continuing medical education and an interactive community for doctors, medical staff such as nurses, medical consultants, speakers, hosts, organisers and sponsors, e.g., the pharmaceutical industry. With 11,000 registered members My Medical Education is the largest database and source for information for those interested in continuing medical education worldwide.

<span class="mw-page-title-main">Vetter Pharma</span>

Vetter Pharma-Fertigung GmbH & Co. KG is a German pharmaceutical service provider founded in 1950. It is headquartered in Ravensburg, Baden-Württemberg, and has production sites in Germany, Austria, the United States, as well as sales offices in Singapore, Japan, and South Korea. The company develops, manufactures and packages aseptically prefilled syringes, cartridges, and vials.

<span class="mw-page-title-main">Life sciences industry in Switzerland</span>

The life sciences industry in Switzerland directly and indirectly employs about 135,000 people. It contributes 5.7% of the gross domestic product of Switzerland and 30% of the country's exports. In 2017 about 30% of Swiss exports were chemical products. In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion.

<span class="mw-page-title-main">August Faller GmbH & Co. KG</span> German Pharmaceutical Secondary Packaging Manufacturer

August Faller GmbH & Co. KG is a German manufacturer and system supplier of pharmaceutical secondary packaging headquartered in Waldkirch, in Baden-Württemberg. With 1147 employees in 6 different locations across Europe, the company produces 2.1 billion folding cartons, 1.6 billion leaflets and 1 billion adhesive labels per year. August Faller GmbH & CO. KG is one of the market leading companies in the field of pharmaceutical secondary packaging in the German-Speaking region.

The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">Wörwag Pharma</span>

Wörwag Pharma is a medium-sized family-owned pharmaceutical company headquartered in Böblingen, Germany with subsidiaries in Asia, Europe and South America. It was founded in 1971 by pharmacist Fritz Wörwag in Stuttgart. It sells prescription and over-the-counter preparations and food supplements.

<span class="mw-page-title-main">Testo SE</span>

Testo SE & Co. KGaA is a company from Lenzkirch, founded in 1957, with its headquarters in Titisee-Neustadt, Germany.

<span class="mw-page-title-main">Pharmaceutical Advertising Advisory Board</span> Canadian not-for-profit organization

The Pharmaceutical Advertising Advisory Board (PAAB) is a Canadian not-for-profit organization based in Pickering, Ontario. Acting as a pseudo-regulatory body, PAAB offers review and pre-clearance services recognized by Health Canada to pharmaceutical companies and marketing agencies who wish to advertise directly to consumers and/or healthcare professionals. It is financed on a fee-for-service basis.

References

  1. 1 2 3 4 5 "At a glance" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  2. ↑ "Imprint". cheplapharm.com. Retrieved 2018-10-11.
  3. 1 2 "Factsheet" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  4. 1 2 "Shareholdings – Pharmaceutical sector". braun-beteiligungen.de. Retrieved 2018-10-11.
  5. ↑ "Pharmafirma investiert 210 Millionen Euro" [Pharmaceutical company to invest 210 Mio. Euro]. ostsee-zeitung.de (in German). 2017-09-01. Archived from the original on 2018-10-13. Retrieved 2018-10-11.
  6. ↑ Lothar Klein (2017-09-01). "Merkel bei Cheplapharm" [Merkel visits Cheplapharm]. apotheke-adhoc.de (in German). Retrieved 2018-10-11.
  7. ↑ "Die 100 größten Unternehmen in Mecklenburg-Vorpommern" [The 100 largest companies in Mecklenburg-Vorpommern](PDF). lfi-mv.de (in German). 2017-12-01. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  8. ↑ Cornelia Meerkatz (2016-11-25). "Die Erfolgs-Familie. Mit Medizin, Mode und Wurst macht die Greifswalder Braun-Gruppe Hunderte Millionen Euro Umsatz" [A successful family. Greifswald-located Braun Group's revenues from pharma, fashion and sausage reach hundreds of millions of euros]. ostsee-zeitung.de (in German). Archived from the original on 2018-10-13. Retrieved 2018-10-11.
  9. 1 2 "Business development" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  10. ↑ "Ich bin ein Schattenbanker" [I am a shadow banker]. sueddeutsche.de (in German). 2017-09-06. Retrieved 2018-10-11.
  11. 1 2 "AZ grants clomethiazole rights to Cheplapharm". scrip.pharmaintelligence.informa.com. 2016-08-01. Retrieved 2018-10-11.
  12. 1 2 "Cheplapharm gets rights to two drugs from Roche". scrip.pharmaintelligence.informa.com. 2016-08-01. Retrieved 2018-10-11.
  13. ↑ Barschneider, M. (February 1959). "[Cheplaren, a plant extract diuretic]". Dtsch Med J. (in German). 10 (3): 63–67. PMID   13639739.
  14. 1 2 Patrick Holstein (2015-02-04). "Riemser reloaded". apotheke-adhoc.de (in German). Retrieved 2018-10-12.
  15. ↑ Patrick Holstein. "Riemser Arzneimittel AG: Auf Expansionskurs mit spezialisiertem Beteiligungskapital" [Riemser Pharma AG: On a course of expansion with specialized equity capital]. bvkap.de (in German). Retrieved 2018-10-12.
  16. 1 2 "Produkte von A bis Z" [Our products from A to Z]. cheplapharm.com (in German). Retrieved 2018-10-12.
  17. ↑ "Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal". cheplapharm.com. 2016-10-27. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  18. ↑ "Cheplapharm acquires product rights for Anexate® from F. Hofmann-La Roche". cheplapharm.com. 2016-01-20. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  19. ↑ "Cheplapharm hat bei den Großen eingekauft" [Cheplapharm has shopped the big name companies]. ostsee-zeitung.de (in German). 2016-01-09. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  20. ↑ "Cheplapharm continues its expansion course and complements its portfolio with four further products". cheplapharm.com. 2018-01-26. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  21. ↑ "Cheplapharm further enhances its portfolio in the Cardiology area". cheplapharm.com. 2018-08-05. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  22. ↑ "Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria". prnewswire.com. 2018-08-07. Retrieved 2018-10-12.
  23. ↑ "Glenwood, LCC". Archived from the original on 2018-10-01. Retrieved 2018-10-12.
  24. ↑ "Cheplapharm France". societe.com. Retrieved 2018-10-12.
  25. ↑ Paolo Bossi (2017-10-28). "Clearum GmbH and Cheplapharm Arzneimittel GmbH estabilishes [sic] Med-Tec Holding GmbH". globallegalchronicle.com. Retrieved 2018-10-12.
  26. ↑ "Pharma- und Medizintechnikfirma gründen neues Unternehmen" [Pharma und medical technology companies found new enterprise]. aerzteblatt.de (in German). 2017-10-20. Retrieved 2018-10-12.
  27. ↑ "Mit Medizintechnik auf den Weltmarkt" [Medical technology for the global market]. nnn.de (in German). 2017-10-21. Retrieved 2018-10-12.
  28. ↑ "Pharma- und Medizintechnikfirma gründen neues Unternehmen" [Pharma und medical technology companies found new enterprise]. welt.de (in German). 2017-10-20. Retrieved 2018-10-12.
  29. ↑ "Dialyse-Filter für China: In Laage entsteht neues Werk" [Dialysis filters for China: New plant to be built in Laage]. ostsee-zeitung.de (in German). 2018-05-24. Retrieved 2018-10-12.
  30. ↑ "LEO Pharma sells four non-core products to Cheplapharm". www.thepharmaletter.com. Retrieved 2022-08-19.
  31. ↑ "Detail|Cheplapharm Greifswald". 2021-01-25. Archived from the original on 2021-01-25. Retrieved 2022-08-19.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  32. ↑ "Cheplapharm kauft mit Latham Wirkstoffe von Takeda und Leo Pharma". juve.de (in German). 2020-09-14. Retrieved 2022-08-19.
  33. ↑ "Greifswald: Cheplapharm sichert sich Rechte an Epilepsie-Medikament Rivotril". www.ostsee-zeitung.de (in German). Retrieved 2022-08-19.
  34. ↑ "Astellas divest legacy products to Cheplapharm; drops vaccine candidat". www.thepharmaletter.com. Retrieved 2022-08-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.